Coeptis bolsters pipeline with two Phase 1
clinical stage assets leveraging NK cell therapies in relapsed or
refractory acute myeloid leukemia (AML)/high risk MDS and
hospitalized respiratory infections, as well as preclinical
programs for hematologic and solid tumors
WEXFORD,
Pa., Aug. 17, 2023 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the
Company"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, announced that it has completed the
exclusive license of key assets from Deverra Therapeutics Inc.
("Deverra") related to its proprietary allogeneic stem cell
expansion and directed differentiation platform for the generation
of multiple distinct immune effector cell types, including natural
killer (NK) and monocyte/macrophages. The transaction enables
Coeptis to further build its pipeline by adding a patented,
elegant, and scalable allogeneic immune cell manufacturing platform
that aligns with its existing SNAP-CAR and GEAR technologies,
increasing the potential for accelerated product development.
As a result of the transaction, Coeptis acquires exclusive
rights to two Investigational New Drug (IND) applications and two
assets in the Phase 1 clinical trial stage (NCT04901416,
NCT04900454) investigating infusion of DVX201, an unmodified
natural killer (NK) cell therapy generated from pooled donor CD34+
cells, in hematologic malignancies and viral infections. In
addition, Coeptis augments its existing portfolio of cell therapy
product candidates with a distinctly scalable allogeneic cellular
immunotherapy platform that is being developed to generate and
deliver off-the-shelf (no HLA matching), cost effective, on-demand
cell therapies to a broad patient population.
In addition to the Phase 1 assets, this transaction equips
Coeptis to begin infusing its existing pipeline assets
with allogeneic technologies that are clinical stage-ready,
helping to accelerate development efforts on targeted novel
products, including potentially the development of allogeneic
engineered NK and MAC cell therapies.
"Finalizing this transaction represents a pivotal transition of
Coeptis into a clinical stage company with novel, synergistic and
differentiated cell therapy pipeline candidates," said Dave Mehalick, President and CEO of Coeptis
Therapeutics. "As we move forward, I am excited to work with
Colleen Delaney, MD, a visionary
scientist whose career has been dedicated to researching and
advancing all aspects of cell therapy product development. A true
leader in the field, Colleen's experience and leadership will be
invaluable as we progress our expanded pipeline towards our
ultimate goal of bringing improved treatments to patients in
need."
Under the transaction, Coeptis paid to Deverra approximately
$570,000 in cash and issued to
Deverra 4,000,000 shares of Coeptis' common stock.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics,
Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical
company developing innovative cell therapy platforms for cancer
that have the potential to disrupt conventional treatment paradigms
and improve patient outcomes. Coeptis' product portfolio and rights
are highlighted by a universal, multi-antigen CAR T technology
licensed from the University of
Pittsburgh (SNAP-CAR), and the GEAR™ cell therapy and
companion diagnostic platforms, which Coeptis is
developing with VyGen-Bio and leading medical researchers at
the Karolinska Institutet. Coeptis' business model is designed
around maximizing the value of its current product portfolio and
rights through in-license agreements, out-license agreements and
co-development relationships, as well as entering into strategic
partnerships to expand its product rights and offerings,
specifically those targeting cancer. The Company is headquartered
in Wexford, PA. For more information on Coeptis
visit https://coeptistx.com/.
About Deverra Therapeutics
Deverra Therapeutics is a privately held clinical stage
biotechnology company dedicated to the development of allogeneic,
off-the-shelf (no matching required) cellular immunotherapies for
on-demand treatment of patients with cancer and infectious
diseases. Deverra is the only company with a proprietary and
clinically proven stem cell expansion technology that also serves
as starting material for generation of multiple fully functional
immune effector cells that can also be engineered to be potent
killers of cancer cells. Deverra was a pioneer developing universal
non-HLA matched allogeneic and off-the-shelf cell therapies that
have been utilized in multiple clinical trials with no safety
concerns.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Capital Market; (2) the risk that the integration of the Deverra
licensed assets will disrupt current plans and operations of the
Company; (3) the inability to recognize the anticipated benefits of
the newly-licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (4) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (5) costs related to integrating the
newly-licensed Deverra assets and pursuing the contemplated asset
development paths; (6) changes in applicable laws or regulations;
(7) the possibility that the Company may be adversely affected by
other economic, business, and/or competitive factors; and (8) the
impact of the global COVID-19 pandemic on any of the foregoing
risks and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission (the "SEC").
The foregoing list of factors is not exclusive. All forward-looking
statements are subject to significant uncertainties and risks
including, but not limited, to those risks contained or to be
contained in reports and other filings filed by the Company with
the SEC. For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the
Company's filings made or to be made with the SEC, which are
available for review at www.sec.gov. We undertake no obligation to
publicly revise these forward-looking statements to reflect events
or circumstances that arise after the date hereof unless required
by applicable laws, regulations, or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Andy Galy, Sr. VP of
Communications
andy.galy@coeptistx.com
Tiberend Strategic Advisors, Inc.
Investors
Daniel
Kontoh-Boateng
dboateng@tiberend.com
Media
David
Schemelia
dschemelia@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-completes-exclusive-license-for-allogeneic-immuno-oncology-platform-and-clinical-stage-assets-from-deverra-therapeutics-301903022.html
SOURCE Coeptis Therapeutics